Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Sarepta Therapeutics, the firm that sells the muscular dystrophy drug eteplirsen, is solidifying its role in the gene-therapy field by acquiring the small start-up Myonexus Therapeutics for $165 million. Myonexus, a spin-off from Nationwide Children’s Hospital in Columbus, Ohio, is developing gene therapies to treat five forms of a rare condition called limb-girdle muscular dystrophy. Sarepta licensed these therapies from Myonexus last May.
This article has been sent to the following recipient: